HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study

Table 3 Susceptibility of the regimen and RT-PR associated resistance mutations

Sample^a	Backbone regimen	RT mutations	PR mutations	Susceptible drugs (including RAL)^b
2	ETV + DRV/r	–	–	3
3	TDF + ZDV + LPV/r	–	–	3
6	TDF/FTC	M184V, V179D	–	2
7	TDF + DRV/r	K103N, Y318F	–	3
8	ETV + DRV/r + T20	E44D, L210W, T215D, K103N, E138G, V179E	V32I, M46I, I54L, V82T, I84V, L33F, T74P	2
11	TDF/FTC + ETV	–	–	4
12	TDF + ZDV + T20	K103N, V108I, H221Y	–	4
13	TDF/FTC + DRV/r	M41L, L74V, M184V, L210W, T215Y, K103S, G190A, F227L	M46L, I54V, I84V, L24M, Q58E	1
14	TDF/FTC	M41L, M184V, T215Y, K103N, K238T	–	1
17	ABC/3TC	M184V	–	1
18	ETV + DRV/r	M184V, K103N, M230L	L33F, M46I, I47V, I54M, V82M	1
19	TDF/FTC	M41L, E44D, D67N, L74V, M184V, L210W, T215Y, K219E, L100I, K103N	L90M	2
21	TPV/r + T20	M41L, A62V, T69D, V75I, Y115F, F116Y, Q151M, M184V, L210W, T215Y, K219R, L100I, K103S, F22FL	V32I, M46I, I54V, V82F, I84V, L90M, L33F, K43T, T74P	2
22	ABC/3TC	M184MIV	–	1
23	TDF + LPV/r	M41L, T215Y	M46I, I54V, V82A, L24I	1
24	TDF/FTC + ATV/r	D67N, T215A, K219Q	–	3
25	EFV + DRV/r	M41L	–	3

RT reverse transcriptase, PR protease, ETV etravirine, DRV/r darunavir and ritonavir, TDF tenofovir, ZDV zidovudine, LPV/r lopinavir and ritonavir, FTC emtricitabine, T20 enfuvirtide, ABC abacavir, 3TC lamivudine, TPV/r tipranavir and ritonavir, EFV efavirenz
^aSamples from subjects with backbone resistance data available
^bNumber of drugs with a predicted resistance score < 15 (T20 was considered susceptible for all cases). n = 17

ISSN: 1742-6405